Use of Pharmacologic Interventions for Breast Cancer Risk Reduction: American Society of Clinical Oncology Clinical Practice Guideline

This clinical practice guideline provides recommendations on pharmacologic interventions for breast cancer risk reduction in women with no personal history of breast cancer who are at increased risk of developing the disease. Tamoxifen, raloxifene, arzoxifene, lasofoxifene, exemestane, and anastrozole are examined as chemoprevention agents. Outcomes of interest include incidence of invasive and noninvasive breast cancer (including ductal carcinoma in situ), breast cancer–specific mortality, overall mortality, net health benefits, quality of life, and adverse events.